[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ec447381a9274cb2925d3a6a913cd81a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[33, 35], [76, 78], [54, 56], [249, 251], [25, 27]], "char_spans": [[169, 175], [441, 447], [287, 293], [1456, 1462], [138, 144]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["translocation", 28], ["(", 42], ["t(9;22", 43], [")", 49], [")", 50], ["results", 52], ["in", 60], ["the", 63], ["molecular", 67], ["juxtaposition", 77], ["of", 91], ["two", 94], ["genes", 98], [",", 103], ["BCR", 105], ["and", 109], ["ABL", 113], [",", 116], ["to", 118], ["form", 121], ["an", 126], ["aberrant", 129], ["BCR", 138], ["-", 141], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["22", 165], [".", 167], ["BCR", 169], ["-", 172], ["ABL", 173], ["is", 177], ["critical", 180], ["to", 189], ["the", 192], ["pathogenesis", 196], ["of", 209], ["chronic", 212], ["myelogenous", 220], ["leukemia", 232], ["and", 241], ["a", 245], ["subset", 247], ["of", 254], ["acute", 257], ["leukemias", 263], [".", 272], ["The", 274], ["chimeric", 278], ["Bcr", 287], ["-", 290], ["Abl", 291], ["protein", 295], ["has", 303], ["constitutively", 307], ["elevated", 322], ["tyrosine", 331], ["phosphokinase", 340], ["activity", 354], [".", 362], ["This", 364], ["abnormal", 369], ["enzymatic", 378], ["activation", 388], ["is", 399], ["critical", 402], ["to", 411], ["the", 414], ["oncogenic", 418], ["potential", 428], ["of", 438], ["Bcr", 441], ["-", 444], ["Abl", 445], [".", 448], ["Initially", 450], [",", 459], ["protein", 461], ["kinases", 469], ["were", 477], ["thought", 482], ["to", 490], ["be", 493], ["poor", 496], ["therapeutic", 501], ["targets", 513], ["because", 521], ["of", 529], ["their", 532], ["ubiquitous", 538], ["nature", 549], ["and", 556], ["crucial", 560], ["role", 568], ["in", 573], ["many", 576], ["normal", 581], ["physiologic", 588], ["processes", 600], [".", 609], ["However", 611], [",", 618], ["the", 620], ["advent", 624], ["of", 631], ["imatinib", 634], ["mesylate", 643], ["(", 652], ["Gleevec", 653], [",", 660], ["Novartis", 662], ["Pharmaceuticals", 671], [",", 686], ["Basel", 688], [",", 693], ["Switzerland", 695], [")", 706], [",", 707], ["formerly", 709], ["known", 718], ["as", 724], ["STI571", 727], ["and", 734], ["CGP57148B", 738], [",", 747], ["demonstrated", 749], ["that", 762], ["designer", 767], ["kinase", 776], ["inhibitors", 783], ["could", 794], ["be", 800], ["specific", 803], [".", 811], ["This", 813], ["agent", 818], ["has", 824], ["shown", 828], ["striking", 834], ["activity", 843], ["in", 852], ["chronic", 855], ["myelogenous", 863], ["leukemia", 875], [".", 883], ["It", 885], ["also", 888], ["inhibits", 893], ["phosphorylation", 902], ["of", 918], ["Kit", 921], ["(", 925], ["stem", 926], ["-", 930], ["cell", 931], ["factor", 936], ["receptor", 943], [")", 951], ["and", 953], ["platelet", 957], ["-", 965], ["derived", 966], ["growth", 974], ["factor", 981], ["receptor", 988], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["has", 1014], ["shown", 1018], ["similar", 1024], ["impressive", 1032], ["responses", 1043], [",", 1052], ["with", 1054], ["little", 1059], ["host", 1066], ["toxicity", 1071], [",", 1079], ["in", 1081], ["gastrointestinal", 1084], ["stromal", 1101], ["tumors", 1109], [",", 1115], ["which", 1117], ["harbor", 1123], ["activating", 1130], ["Kit", 1141], ["mutations", 1145], [",", 1154], ["and", 1156], ["in", 1160], ["tumors", 1163], ["with", 1170], ["activated", 1175], ["platelet", 1185], ["-", 1193], ["derived", 1194], ["growth", 1202], ["factor", 1209], ["receptor", 1216], [".", 1224], ["The", 1226], ["studies", 1230], ["of", 1238], ["imatinib", 1241], ["mesylate", 1250], ["provide", 1259], ["proof", 1267], ["-", 1272], ["of", 1273], ["-", 1275], ["principle", 1276], ["for", 1286], ["using", 1290], ["aberrant", 1296], ["kinases", 1305], ["as", 1313], ["a", 1316], ["therapeutic", 1318], ["target", 1330], ["and", 1337], ["are", 1341], ["a", 1345], ["model", 1347], ["for", 1353], ["the", 1357], ["promise", 1361], ["of", 1369], ["molecular", 1372], ["therapeutics", 1382], [".", 1394], ["This", 1396], ["paper", 1401], ["reviews", 1407], ["the", 1415], ["current", 1419], ["knowledge", 1427], ["on", 1437], ["the", 1440], ["function", 1444], ["of", 1453], ["Bcr", 1456], ["-", 1459], ["Abl", 1460], ["and", 1464], ["its", 1468], ["normal", 1472], ["counterparts", 1479], ["(", 1492], ["Bcr", 1493], ["and", 1497], ["Abl", 1501], [")", 1504], [",", 1505], ["as", 1507], ["well", 1510], ["as", 1515], ["the", 1518], ["impact", 1522], ["of", 1529], ["this", 1532], ["knowledge", 1537], ["on", 1547], ["the", 1550], ["development", 1554], ["of", 1566], ["a", 1569], ["remarkably", 1571], ["successful", 1582], ["targeted", 1593], ["therapy", 1602], ["approach", 1610], [".", 1618]]}
{"context": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data. Impact of RLS on quality of life and health has been studied primarily in industrialized countries, particularly Europe and the United States. Many studies have relied exclusively on self-report of symptoms or have assessed only medical populations. Recently, interest has emerged on the impact of WED in rural, underserved populations globally. In a population-based survey conducted in rural Ecuador, we assessed the relationship of psychological distress to WED, evaluated with the Depression Anxiety Stress Scales-21. WED was diagnosed through a 2-phase method in which all residents were screened with the International Restless Legs Syndrome Study Group (IRLSSG) questionnaire and all suspected cases were subsequently confirmed through expert medical examination. WED severity was assessed with the IRLSSG rating scale. Of 665 persons (mean [SD] age, 59.5 [12.6] years; women, 386 [58%]), 76 had depression, 93 had anxiety, and 60 reported stress. Forty persons (6%) had WED, with 15 (38%) having severe disease. In a regression model adjusted for age and sex, the prevalence of depression, anxiety, and stress was about 3 times greater among persons with WED than the general population. Although cross-sectional data cannot establish causation, this study shows the large behavioral health burden associated with WED in an untreated, rural population.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "5dc7b7888b6a4035ae95f669a8d8cfff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[139, 141], [3, 5]], "char_spans": [[811, 832], [23, 44]]}]}], "context_tokens": [["Reported", 0], ["prevalence", 9], ["of", 20], ["restless", 23], ["legs", 32], ["syndrome", 37], ["(", 46], ["RLS", 47], [")", 50], [",", 51], ["also", 53], ["known", 58], ["as", 64], ["Willis", 67], ["-", 73], ["Ekbom", 74], ["disease", 80], ["(", 88], ["WED", 89], [")", 92], [",", 93], ["varies", 95], ["from", 102], ["country", 107], ["to", 115], ["country", 118], [",", 125], ["and", 127], ["methodologic", 131], ["inconsistencies", 144], ["limit", 160], ["comparison", 166], ["of", 177], ["data", 180], [".", 184], ["Impact", 186], ["of", 193], ["RLS", 196], ["on", 200], ["quality", 203], ["of", 211], ["life", 214], ["and", 219], ["health", 223], ["has", 230], ["been", 234], ["studied", 239], ["primarily", 247], ["in", 257], ["industrialized", 260], ["countries", 275], [",", 284], ["particularly", 286], ["Europe", 299], ["and", 306], ["the", 310], ["United", 314], ["States", 321], [".", 327], ["Many", 329], ["studies", 334], ["have", 342], ["relied", 347], ["exclusively", 354], ["on", 366], ["self", 369], ["-", 373], ["report", 374], ["of", 381], ["symptoms", 384], ["or", 393], ["have", 396], ["assessed", 401], ["only", 410], ["medical", 415], ["populations", 423], [".", 434], ["Recently", 436], [",", 444], ["interest", 446], ["has", 455], ["emerged", 459], ["on", 467], ["the", 470], ["impact", 474], ["of", 481], ["WED", 484], ["in", 488], ["rural", 491], [",", 496], ["underserved", 498], ["populations", 510], ["globally", 522], [".", 530], ["In", 532], ["a", 535], ["population", 537], ["-", 547], ["based", 548], ["survey", 554], ["conducted", 561], ["in", 571], ["rural", 574], ["Ecuador", 580], [",", 587], ["we", 589], ["assessed", 592], ["the", 601], ["relationship", 605], ["of", 618], ["psychological", 621], ["distress", 635], ["to", 644], ["WED", 647], [",", 650], ["evaluated", 652], ["with", 662], ["the", 667], ["Depression", 671], ["Anxiety", 682], ["Stress", 690], ["Scales-21", 697], [".", 706], ["WED", 708], ["was", 712], ["diagnosed", 716], ["through", 726], ["a", 734], ["2-phase", 736], ["method", 744], ["in", 751], ["which", 754], ["all", 760], ["residents", 764], ["were", 774], ["screened", 779], ["with", 788], ["the", 793], ["International", 797], ["Restless", 811], ["Legs", 820], ["Syndrome", 825], ["Study", 834], ["Group", 840], ["(", 846], ["IRLSSG", 847], [")", 853], ["questionnaire", 855], ["and", 869], ["all", 873], ["suspected", 877], ["cases", 887], ["were", 893], ["subsequently", 898], ["confirmed", 911], ["through", 921], ["expert", 929], ["medical", 936], ["examination", 944], [".", 955], ["WED", 957], ["severity", 961], ["was", 970], ["assessed", 974], ["with", 983], ["the", 988], ["IRLSSG", 992], ["rating", 999], ["scale", 1006], [".", 1011], ["Of", 1013], ["665", 1016], ["persons", 1020], ["(", 1028], ["mean", 1029], ["[", 1034], ["SD", 1035], ["]", 1037], ["age", 1039], [",", 1042], ["59.5", 1044], ["[", 1049], ["12.6", 1050], ["]", 1054], ["years", 1056], [";", 1061], ["women", 1063], [",", 1068], ["386", 1070], ["[", 1074], ["58", 1075], ["%", 1077], ["]", 1078], [")", 1079], [",", 1080], ["76", 1082], ["had", 1085], ["depression", 1089], [",", 1099], ["93", 1101], ["had", 1104], ["anxiety", 1108], [",", 1115], ["and", 1117], ["60", 1121], ["reported", 1124], ["stress", 1133], [".", 1139], ["Forty", 1141], ["persons", 1147], ["(", 1155], ["6", 1156], ["%", 1157], [")", 1158], ["had", 1160], ["WED", 1164], [",", 1167], ["with", 1169], ["15", 1174], ["(", 1177], ["38", 1178], ["%", 1180], [")", 1181], ["having", 1183], ["severe", 1190], ["disease", 1197], [".", 1204], ["In", 1206], ["a", 1209], ["regression", 1211], ["model", 1222], ["adjusted", 1228], ["for", 1237], ["age", 1241], ["and", 1245], ["sex", 1249], [",", 1252], ["the", 1254], ["prevalence", 1258], ["of", 1269], ["depression", 1272], [",", 1282], ["anxiety", 1284], [",", 1291], ["and", 1293], ["stress", 1297], ["was", 1304], ["about", 1308], ["3", 1314], ["times", 1316], ["greater", 1322], ["among", 1330], ["persons", 1336], ["with", 1344], ["WED", 1349], ["than", 1353], ["the", 1358], ["general", 1362], ["population", 1370], [".", 1380], ["Although", 1382], ["cross", 1391], ["-", 1396], ["sectional", 1397], ["data", 1407], ["can", 1412], ["not", 1415], ["establish", 1419], ["causation", 1429], [",", 1438], ["this", 1440], ["study", 1445], ["shows", 1451], ["the", 1457], ["large", 1461], ["behavioral", 1467], ["health", 1478], ["burden", 1485], ["associated", 1492], ["with", 1503], ["WED", 1508], ["in", 1512], ["an", 1515], ["untreated", 1518], [",", 1527], ["rural", 1529], ["population", 1535], [".", 1545]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Chaperone-mediated autophagy is one of several lysosomal pathways of proteolysis. This pathway is activated by physiological stresses such as prolonged starvation. Cytosolic proteins with particular peptide sequence motifs are recognized by a complex of molecular chaperones and delivered to lysosomes. No vesicular traffic is required for this protein degradation pathway, so it differs from microautophagy and macroautophagy. Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a. Levels of lamp2a in the lysosomal membrane are controlled by alterations in the lamp2a half-life as well as by the dynamic distribution of the protein between the lysosomal membrane and the lumen. Substrate proteins are unfolded before transport into the lysosome lumen, and the transport of substrate proteins requires a molecular chaperone within the lysosomal lumen. The exact roles of this lysosomal chaperone remain to be defined. The mechanisms of chaperone-mediated autophagy are similar to mechanisms of protein import into mitochondria, chloroplasts, and the endoplasmic reticulum.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "2af13c4b405e44c8820036a07143c462", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[100, 100], [89, 89]], "char_spans": [[630, 635], [560, 565]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["is", 29], ["one", 32], ["of", 36], ["several", 39], ["lysosomal", 47], ["pathways", 57], ["of", 66], ["proteolysis", 69], [".", 80], ["This", 82], ["pathway", 87], ["is", 95], ["activated", 98], ["by", 108], ["physiological", 111], ["stresses", 125], ["such", 134], ["as", 139], ["prolonged", 142], ["starvation", 152], [".", 162], ["Cytosolic", 164], ["proteins", 174], ["with", 183], ["particular", 188], ["peptide", 199], ["sequence", 207], ["motifs", 216], ["are", 223], ["recognized", 227], ["by", 238], ["a", 241], ["complex", 243], ["of", 251], ["molecular", 254], ["chaperones", 264], ["and", 275], ["delivered", 279], ["to", 289], ["lysosomes", 292], [".", 301], ["No", 303], ["vesicular", 306], ["traffic", 316], ["is", 324], ["required", 327], ["for", 336], ["this", 340], ["protein", 345], ["degradation", 353], ["pathway", 365], [",", 372], ["so", 374], ["it", 377], ["differs", 380], ["from", 388], ["microautophagy", 393], ["and", 408], ["macroautophagy", 412], [".", 426], ["Protein", 428], ["substrates", 436], ["bind", 447], ["to", 452], ["a", 455], ["receptor", 457], ["in", 466], ["the", 469], ["lysosomal", 473], ["membrane", 483], [",", 491], ["the", 493], ["lysosome", 497], ["-", 505], ["associated", 506], ["membrane", 517], ["protein", 526], ["(", 534], ["lamp", 535], [")", 539], ["type", 541], ["2a", 546], [".", 548], ["Levels", 550], ["of", 557], ["lamp2a", 560], ["in", 567], ["the", 570], ["lysosomal", 574], ["membrane", 584], ["are", 593], ["controlled", 597], ["by", 608], ["alterations", 611], ["in", 623], ["the", 626], ["lamp2a", 630], ["half", 637], ["-", 641], ["life", 642], ["as", 647], ["well", 650], ["as", 655], ["by", 658], ["the", 661], ["dynamic", 665], ["distribution", 673], ["of", 686], ["the", 689], ["protein", 693], ["between", 701], ["the", 709], ["lysosomal", 713], ["membrane", 723], ["and", 732], ["the", 736], ["lumen", 740], [".", 745], ["Substrate", 747], ["proteins", 757], ["are", 766], ["unfolded", 770], ["before", 779], ["transport", 786], ["into", 796], ["the", 801], ["lysosome", 805], ["lumen", 814], [",", 819], ["and", 821], ["the", 825], ["transport", 829], ["of", 839], ["substrate", 842], ["proteins", 852], ["requires", 861], ["a", 870], ["molecular", 872], ["chaperone", 882], ["within", 892], ["the", 899], ["lysosomal", 903], ["lumen", 913], [".", 918], ["The", 920], ["exact", 924], ["roles", 930], ["of", 936], ["this", 939], ["lysosomal", 944], ["chaperone", 954], ["remain", 964], ["to", 971], ["be", 974], ["defined", 977], [".", 984], ["The", 986], ["mechanisms", 990], ["of", 1001], ["chaperone", 1004], ["-", 1013], ["mediated", 1014], ["autophagy", 1023], ["are", 1033], ["similar", 1037], ["to", 1045], ["mechanisms", 1048], ["of", 1059], ["protein", 1062], ["import", 1070], ["into", 1077], ["mitochondria", 1082], [",", 1094], ["chloroplasts", 1096], [",", 1108], ["and", 1110], ["the", 1114], ["endoplasmic", 1118], ["reticulum", 1130], [".", 1139]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "Cells respond to stresses such as osmotic shock and heat shock by activating stress-activated protein kinases (SAPKs), including c-Jun N-terminal kinase (JNK) [1]. Activation of JNK requires phosphorylation of threonine and tyrosine residues in the TPY activation loop motif [2, 3] and can be reversed by the removal of either phosphate group. Numerous JNK phosphatases including dual-specificity phosphatases [4, 5], have been identified. Many stimuli activate JNK by increasing its rate of phosphorylation; however, JNK dephosphorylation is inhibited in cells after heat shock [6], suggesting that a JNK phosphatase(s) is inactivated. M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. We have previously expressed M3/6 in the mouse bone marrow cell line BAF3 in order to show that JNK activation by IL-3 is necessary for cell survival and proliferation [9]. Here we report that M3/6 dissociates from JNK and appears in an insoluble fraction after heat shock. These data identify M3/6 as a JNK phosphatase that is inactivated by heat shock and provide a molecular mechanism for the activation of JNK by heat shock.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "902996f009de41b18ed94ad607438522", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[37, 37], [69, 69], [99, 99], [115, 115], [173, 173], [89, 89], [153, 153], [190, 190], [130, 130], [31, 31], [207, 207]], "char_spans": [[178, 180], [353, 355], [518, 520], [602, 604], [917, 919], [462, 464], [798, 800], [1006, 1008], [690, 692], [154, 156], [1112, 1114]]}]}], "context_tokens": [["Cells", 0], ["respond", 6], ["to", 14], ["stresses", 17], ["such", 26], ["as", 31], ["osmotic", 34], ["shock", 42], ["and", 48], ["heat", 52], ["shock", 57], ["by", 63], ["activating", 66], ["stress", 77], ["-", 83], ["activated", 84], ["protein", 94], ["kinases", 102], ["(", 110], ["SAPKs", 111], [")", 116], [",", 117], ["including", 119], ["c", 129], ["-", 130], ["Jun", 131], ["N", 135], ["-", 136], ["terminal", 137], ["kinase", 146], ["(", 153], ["JNK", 154], [")", 157], ["[", 159], ["1].", 160], ["Activation", 164], ["of", 175], ["JNK", 178], ["requires", 182], ["phosphorylation", 191], ["of", 207], ["threonine", 210], ["and", 220], ["tyrosine", 224], ["residues", 233], ["in", 242], ["the", 245], ["TPY", 249], ["activation", 253], ["loop", 264], ["motif", 269], ["[", 275], ["2", 276], [",", 277], ["3", 279], ["]", 280], ["and", 282], ["can", 286], ["be", 290], ["reversed", 293], ["by", 302], ["the", 305], ["removal", 309], ["of", 317], ["either", 320], ["phosphate", 327], ["group", 337], [".", 342], ["Numerous", 344], ["JNK", 353], ["phosphatases", 357], ["including", 370], ["dual", 380], ["-", 384], ["specificity", 385], ["phosphatases", 397], ["[", 410], ["4", 411], [",", 412], ["5", 414], ["]", 415], [",", 416], ["have", 418], ["been", 423], ["identified", 428], [".", 438], ["Many", 440], ["stimuli", 445], ["activate", 453], ["JNK", 462], ["by", 466], ["increasing", 469], ["its", 480], ["rate", 484], ["of", 489], ["phosphorylation", 492], [";", 507], ["however", 509], [",", 516], ["JNK", 518], ["dephosphorylation", 522], ["is", 540], ["inhibited", 543], ["in", 553], ["cells", 556], ["after", 562], ["heat", 568], ["shock", 573], ["[", 579], ["6", 580], ["]", 581], [",", 582], ["suggesting", 584], ["that", 595], ["a", 600], ["JNK", 602], ["phosphatase(s", 606], [")", 619], ["is", 621], ["inactivated", 624], [".", 635], ["M3/6", 637], ["is", 642], ["a", 645], ["dual", 647], ["-", 651], ["specificity", 652], ["phosphatase", 664], ["selective", 676], ["for", 686], ["JNK", 690], ["[", 694], ["7", 695], [",", 696], ["8].", 698], ["We", 702], ["have", 705], ["previously", 710], ["expressed", 721], ["M3/6", 731], ["in", 736], ["the", 739], ["mouse", 743], ["bone", 749], ["marrow", 754], ["cell", 761], ["line", 766], ["BAF3", 771], ["in", 776], ["order", 779], ["to", 785], ["show", 788], ["that", 793], ["JNK", 798], ["activation", 802], ["by", 813], ["IL-3", 816], ["is", 821], ["necessary", 824], ["for", 834], ["cell", 838], ["survival", 843], ["and", 852], ["proliferation", 856], ["[", 870], ["9].", 871], ["Here", 875], ["we", 880], ["report", 883], ["that", 890], ["M3/6", 895], ["dissociates", 900], ["from", 912], ["JNK", 917], ["and", 921], ["appears", 925], ["in", 933], ["an", 936], ["insoluble", 939], ["fraction", 949], ["after", 958], ["heat", 964], ["shock", 969], [".", 974], ["These", 976], ["data", 982], ["identify", 987], ["M3/6", 996], ["as", 1001], ["a", 1004], ["JNK", 1006], ["phosphatase", 1010], ["that", 1022], ["is", 1027], ["inactivated", 1030], ["by", 1042], ["heat", 1045], ["shock", 1050], ["and", 1056], ["provide", 1060], ["a", 1068], ["molecular", 1070], ["mechanism", 1080], ["for", 1090], ["the", 1094], ["activation", 1098], ["of", 1109], ["JNK", 1112], ["by", 1116], ["heat", 1119], ["shock", 1124], [".", 1129]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA (siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "da99a2b47daf44bb94a87ccf477bf308", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[87, 89]], "char_spans": [[486, 518]]}]}], "context_tokens": [["Mgm1", 0], ["is", 5], ["a", 8], ["member", 10], ["of", 17], ["the", 20], ["dynamin", 24], ["family", 32], ["of", 39], ["GTP", 42], ["-", 45], ["binding", 46], ["proteins", 54], [".", 62], ["Mgm1", 64], ["was", 69], ["first", 73], ["identified", 79], ["in", 90], ["yeast", 93], [",", 98], ["where", 100], ["it", 106], ["affects", 109], ["mitochondrial", 117], ["morphology", 131], [".", 141], ["The", 143], ["human", 147], ["homologue", 153], ["of", 163], ["Mgm1", 166], ["is", 171], ["called", 174], ["OPA1", 181], [".", 185], ["Mutations", 187], ["in", 197], ["the", 200], ["OPA1", 204], ["gene", 209], ["are", 214], ["the", 218], ["prevailing", 222], ["cause", 233], ["of", 239], ["dominant", 242], ["optic", 251], ["atrophy", 257], [",", 264], ["a", 266], ["hereditary", 268], ["disease", 279], ["in", 287], ["which", 290], ["progressive", 296], ["degeneration", 308], ["of", 321], ["the", 324], ["optic", 328], ["nerve", 334], ["can", 340], ["lead", 344], ["to", 349], ["blindness", 352], [".", 361], ["Here", 363], ["we", 368], ["investigate", 371], ["the", 383], ["properties", 387], ["of", 398], ["the", 401], ["Mgm1/OPA1", 405], ["protein", 415], ["in", 423], ["mammalian", 426], ["cells", 436], [".", 441], ["We", 443], ["find", 446], ["that", 451], ["Mgm1/OPA1", 456], ["is", 466], ["localized", 469], ["to", 479], ["the", 482], ["mitochondrial", 486], ["intermembrane", 500], ["space", 514], [",", 519], ["where", 521], ["it", 527], ["is", 530], ["tightly", 533], ["bound", 541], ["to", 547], ["the", 550], ["outer", 554], ["surface", 560], ["of", 568], ["the", 571], ["inner", 575], ["membrane", 581], [".", 589], ["Overexpression", 591], ["of", 606], ["wild", 609], ["type", 614], ["or", 619], ["mutant", 622], ["forms", 629], ["of", 635], ["the", 638], ["Mgm1/OPA1", 642], ["protein", 652], ["cause", 660], ["mitochondria", 666], ["to", 679], ["fragment", 682], ["and", 691], [",", 694], ["in", 696], ["some", 699], ["cases", 704], [",", 709], ["cluster", 711], ["near", 719], ["the", 724], ["nucleus", 728], [",", 735], ["whereas", 737], ["the", 745], ["loss", 749], ["of", 754], ["protein", 757], ["caused", 765], ["by", 772], ["small", 775], ["interfering", 781], ["RNA", 793], ["(", 797], ["siRNA", 798], [")", 803], ["leads", 805], ["to", 811], ["dispersal", 814], ["of", 824], ["mitochondrial", 827], ["fragments", 841], ["throughout", 851], ["the", 862], ["cytosol", 866], [".", 873], ["The", 875], ["cristae", 879], ["of", 887], ["these", 890], ["fragmented", 896], ["mitochondria", 907], ["are", 920], ["disorganized", 924], [".", 936], ["At", 938], ["early", 941], ["time", 947], ["points", 952], ["after", 959], ["transfection", 965], ["with", 978], ["Mgm1/OPA1", 983], ["siRNA", 993], [",", 998], ["the", 1000], ["mitochondria", 1004], ["are", 1017], ["not", 1021], ["yet", 1025], ["fragmented", 1029], [".", 1039], ["Instead", 1041], [",", 1048], ["the", 1050], ["mitochondria", 1054], ["swell", 1067], ["and", 1073], ["stretch", 1077], [",", 1084], ["after", 1086], ["which", 1092], ["they", 1098], ["form", 1103], ["localized", 1108], ["constrictions", 1118], ["similar", 1132], ["to", 1140], ["the", 1143], ["mitochondrial", 1147], ["abnormalities", 1161], ["observed", 1175], ["during", 1184], ["the", 1191], ["early", 1195], ["stages", 1201], ["of", 1208], ["apoptosis", 1211], [".", 1220], ["These", 1222], ["abnormalities", 1228], ["might", 1242], ["be", 1248], ["the", 1251], ["earliest", 1255], ["effects", 1264], ["of", 1272], ["losing", 1275], ["Mgm1/OPA1", 1282], ["protein", 1292], [".", 1299]]}
{"context": "Objective. A study to determine if addition of palatal petechiae to Centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. Hypothesis. In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis. We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children. Methods. One hundred patients with a complaint of sore throat were enrolled in the study. All the patients were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. All the patients were given rapid strep tests, and throat cultures were sent. No antibiotics were given until culture results were obtained. Results. The sample size was 100 patients. All 100 had fever, sore throat, and erythema of tonsils. Twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. In total, 9 out of the 100 patients had positive throat cultures. We observed that petechiae over the palate, a very significant sign, is not included in the Centor Criteria. Palatal petechiae were present in 8 out of the 100 patients. Six out of these 8 with palatal petechiae had positive throat culture for strep (75%). Only 7 out of 20 with exudates had positive strep culture. Sixteen out of the 100 patients had rapid strep test positive. Those 84/100 who had negative rapid strep also had negative throat culture. Statistics. We used Fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant P value <.0001. Conclusion. Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "345cc6f39eb0472ebb37229e6f4e34b1", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[356, 357], [67, 68]], "char_spans": [[1984, 2008], [406, 430]]}]}], "context_tokens": [["Objective", 0], [".", 9], ["A", 11], ["study", 13], ["to", 19], ["determine", 22], ["if", 32], ["addition", 35], ["of", 44], ["palatal", 47], ["petechiae", 55], ["to", 65], ["Centor", 68], ["criteria", 75], ["adds", 84], ["more", 89], ["value", 94], ["for", 100], ["clinical", 104], ["diagnosis", 113], ["of", 123], ["acute", 126], ["strep", 132], ["pharyngitis", 138], ["in", 150], ["children", 153], [".", 161], ["Hypothesis", 163], [".", 173], ["In", 175], ["children", 178], [",", 186], ["Centor", 188], ["Criteria", 195], ["does", 204], ["not", 209], ["cover", 213], ["all", 219], ["the", 223], ["symptoms", 227], ["and", 236], ["signs", 240], ["of", 246], ["acute", 249], ["strep", 255], ["pharyngitis", 261], [".", 272], ["We", 274], ["hypothesize", 277], ["that", 289], ["addition", 294], ["of", 303], ["palatal", 306], ["petechiae", 314], ["to", 324], ["Centor", 327], ["Criteria", 334], ["will", 343], ["increase", 348], ["the", 357], ["possibility", 361], ["of", 373], ["clinical", 376], ["diagnosis", 385], ["of", 395], ["group", 398], ["A", 404], ["streptococcal", 406], ["pharyngitis", 420], ["in", 432], ["children", 435], [".", 443], ["Methods", 445], [".", 452], ["One", 454], ["hundred", 458], ["patients", 466], ["with", 475], ["a", 480], ["complaint", 482], ["of", 492], ["sore", 495], ["throat", 500], ["were", 507], ["enrolled", 512], ["in", 521], ["the", 524], ["study", 528], [".", 533], ["All", 535], ["the", 539], ["patients", 543], ["were", 552], ["examined", 557], ["clinically", 566], ["using", 577], ["the", 583], ["Centor", 587], ["Criteria", 594], [".", 602], ["They", 604], ["were", 609], ["also", 614], ["examined", 619], ["for", 628], ["other", 632], ["signs", 638], ["and", 644], ["symptoms", 648], ["like", 657], ["petechial", 662], ["lesions", 672], ["over", 680], ["the", 685], ["palate", 689], [",", 695], ["abdominal", 697], ["pain", 707], [",", 711], ["and", 713], ["skin", 717], ["rash", 722], [".", 726], ["All", 728], ["the", 732], ["patients", 736], ["were", 745], ["given", 750], ["rapid", 756], ["strep", 762], ["tests", 768], [",", 773], ["and", 775], ["throat", 779], ["cultures", 786], ["were", 795], ["sent", 800], [".", 804], ["No", 806], ["antibiotics", 809], ["were", 821], ["given", 826], ["until", 832], ["culture", 838], ["results", 846], ["were", 854], ["obtained", 859], [".", 867], ["Results", 869], [".", 876], ["The", 878], ["sample", 882], ["size", 889], ["was", 894], ["100", 898], ["patients", 902], [".", 910], ["All", 912], ["100", 916], ["had", 920], ["fever", 924], [",", 929], ["sore", 931], ["throat", 936], [",", 942], ["and", 944], ["erythema", 948], ["of", 957], ["tonsils", 960], [".", 967], ["Twenty", 969], ["of", 976], ["the", 979], ["100", 983], ["patients", 987], ["had", 996], ["tonsillar", 1000], ["exudates", 1010], [",", 1018], ["85/100", 1020], ["had", 1027], ["tender", 1031], ["anterior", 1038], ["cervical", 1047], ["lymph", 1056], ["nodes", 1062], [",", 1067], ["and", 1069], ["86/100", 1073], ["had", 1080], ["no", 1084], ["cough", 1087], [".", 1092], ["In", 1094], ["total", 1097], [",", 1102], ["9", 1104], ["out", 1106], ["of", 1110], ["the", 1113], ["100", 1117], ["patients", 1121], ["had", 1130], ["positive", 1134], ["throat", 1143], ["cultures", 1150], [".", 1158], ["We", 1160], ["observed", 1163], ["that", 1172], ["petechiae", 1177], ["over", 1187], ["the", 1192], ["palate", 1196], [",", 1202], ["a", 1204], ["very", 1206], ["significant", 1211], ["sign", 1223], [",", 1227], ["is", 1229], ["not", 1232], ["included", 1236], ["in", 1245], ["the", 1248], ["Centor", 1252], ["Criteria", 1259], [".", 1267], ["Palatal", 1269], ["petechiae", 1277], ["were", 1287], ["present", 1292], ["in", 1300], ["8", 1303], ["out", 1305], ["of", 1309], ["the", 1312], ["100", 1316], ["patients", 1320], [".", 1328], ["Six", 1330], ["out", 1334], ["of", 1338], ["these", 1341], ["8", 1347], ["with", 1349], ["palatal", 1354], ["petechiae", 1362], ["had", 1372], ["positive", 1376], ["throat", 1385], ["culture", 1392], ["for", 1400], ["strep", 1404], ["(", 1410], ["75", 1411], ["%", 1413], [")", 1414], [".", 1415], ["Only", 1417], ["7", 1422], ["out", 1424], ["of", 1428], ["20", 1431], ["with", 1434], ["exudates", 1439], ["had", 1448], ["positive", 1452], ["strep", 1461], ["culture", 1467], [".", 1474], ["Sixteen", 1476], ["out", 1484], ["of", 1488], ["the", 1491], ["100", 1495], ["patients", 1499], ["had", 1508], ["rapid", 1512], ["strep", 1518], ["test", 1524], ["positive", 1529], [".", 1537], ["Those", 1539], ["84/100", 1545], ["who", 1552], ["had", 1556], ["negative", 1560], ["rapid", 1569], ["strep", 1575], ["also", 1581], ["had", 1586], ["negative", 1590], ["throat", 1599], ["culture", 1606], [".", 1613], ["Statistics", 1615], [".", 1625], ["We", 1627], ["used", 1630], ["Fisher", 1635], ["'s", 1641], ["exact", 1644], ["test", 1650], [",", 1654], ["comparing", 1656], ["throat", 1666], ["culture", 1673], ["positive", 1681], ["and", 1690], ["negative", 1694], ["versus", 1703], ["presence", 1710], ["of", 1719], ["exudates", 1722], ["and", 1731], ["palatal", 1735], ["hemorrhages", 1743], ["with", 1755], ["positive", 1760], ["and", 1769], ["negative", 1773], ["throat", 1782], ["cultures", 1789], ["and", 1798], ["the", 1802], ["resultant", 1806], ["P", 1816], ["value", 1818], ["<", 1824], [".0001", 1825], [".", 1830], ["Conclusion", 1832], [".", 1842], ["Our", 1844], ["study", 1848], ["concludes", 1854], ["that", 1864], ["addition", 1869], ["of", 1878], ["petechiae", 1881], ["over", 1891], ["the", 1896], ["palate", 1900], ["to", 1907], ["Centor", 1910], ["Criteria", 1917], ["will", 1926], ["increase", 1931], ["the", 1940], ["possibility", 1944], ["of", 1956], ["diagnosing", 1959], ["acute", 1970], ["group", 1976], ["A", 1982], ["streptococcal", 1984], ["pharyngitis", 1998], ["in", 2010], ["children", 2013], [".", 2021]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Hereditary long QT syndrome (LQTS) is a genetically heterogeneous disease characterized by prolonged QT intervals and an increased risk for ventricular arrhythmias and sudden cardiac death. Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias. In this study, we investigate and discuss dominant-negative I(Ks) current reduction by a KCNQ1 deletion mutation identified in a RWS family. Single-strand conformation polymorphism analysis and direct sequencing were used to screen LQTS genes for mutations. Mutant KCNQ1 channels were heterologously expressed in Xenopus oocytes, and potassium currents were recorded using the two-microelectrode voltage clamp technique. A heterozygous deletion of three nucleotides (CTT) identified in the KCNQ1 gene caused the loss of a single phenylalanine residue at position 339 (KCNQ1-deltaF339). Electrophysiological measurements in the presence and absence of the regulatory beta-subunit KCNE1 revealed that mutant and wild type forms of an N-terminal truncated KCNQ1 subunit (isoform 2) caused much stronger dominant-negative current reduction than the mutant form of the full-length KCNQ1 subunit (isoform 1). This study highlights the functional relevance of the truncated KCNQ1 splice variant (isoform 2) in establishment and mode of inheritance in long QT syndrome. In the RWS family presented here, the autosomal-dominant trait is caused by multiple dominant-negative effects provoked by heteromultimeric channels formed by wild type and mutant KCNQ1-isoforms in combination with KCNE1.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "3c809ea1a7604eca9f5319c8cf28554b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[282, 284], [58, 60]], "char_spans": [[1640, 1657], [351, 368]]}]}], "context_tokens": [["Hereditary", 0], ["long", 11], ["QT", 16], ["syndrome", 19], ["(", 28], ["LQTS", 29], [")", 33], ["is", 35], ["a", 38], ["genetically", 40], ["heterogeneous", 52], ["disease", 66], ["characterized", 74], ["by", 88], ["prolonged", 91], ["QT", 101], ["intervals", 104], ["and", 114], ["an", 118], ["increased", 121], ["risk", 131], ["for", 136], ["ventricular", 140], ["arrhythmias", 152], ["and", 164], ["sudden", 168], ["cardiac", 175], ["death", 183], [".", 188], ["Mutations", 190], ["in", 200], ["the", 203], ["voltage", 207], ["-", 214], ["gated", 215], ["potassium", 221], ["channel", 231], ["subunit", 239], ["KCNQ1", 247], ["induce", 253], ["the", 260], ["most", 264], ["common", 269], ["form", 276], ["of", 281], ["LQTS", 284], [".", 288], ["KCNQ1", 290], ["is", 296], ["associated", 299], ["with", 310], ["two", 315], ["different", 319], ["entities", 329], ["of", 338], ["LQTS", 341], [",", 345], ["the", 347], ["autosomal", 351], ["-", 360], ["dominant", 361], ["Romano", 370], ["-", 376], ["Ward", 377], ["syndrome", 382], ["(", 391], ["RWS", 392], [")", 395], [",", 396], ["and", 398], ["the", 402], ["autosomal", 406], ["-", 415], ["recessive", 416], ["Jervell", 426], ["and", 434], ["Lange", 438], ["-", 443], ["Nielsen", 444], ["syndrome", 452], ["(", 461], ["JLNS", 462], [")", 466], ["characterized", 468], ["by", 482], ["bilateral", 485], ["deafness", 495], ["in", 504], ["addition", 507], ["to", 516], ["cardiac", 519], ["arrhythmias", 527], [".", 538], ["In", 540], ["this", 543], ["study", 548], [",", 553], ["we", 555], ["investigate", 558], ["and", 570], ["discuss", 574], ["dominant", 582], ["-", 590], ["negative", 591], ["I(Ks", 600], [")", 604], ["current", 606], ["reduction", 614], ["by", 624], ["a", 627], ["KCNQ1", 629], ["deletion", 635], ["mutation", 644], ["identified", 653], ["in", 664], ["a", 667], ["RWS", 669], ["family", 673], [".", 679], ["Single", 681], ["-", 687], ["strand", 688], ["conformation", 695], ["polymorphism", 708], ["analysis", 721], ["and", 730], ["direct", 734], ["sequencing", 741], ["were", 752], ["used", 757], ["to", 762], ["screen", 765], ["LQTS", 772], ["genes", 777], ["for", 783], ["mutations", 787], [".", 796], ["Mutant", 798], ["KCNQ1", 805], ["channels", 811], ["were", 820], ["heterologously", 825], ["expressed", 840], ["in", 850], ["Xenopus", 853], ["oocytes", 861], [",", 868], ["and", 870], ["potassium", 874], ["currents", 884], ["were", 893], ["recorded", 898], ["using", 907], ["the", 913], ["two", 917], ["-", 920], ["microelectrode", 921], ["voltage", 936], ["clamp", 944], ["technique", 950], [".", 959], ["A", 961], ["heterozygous", 963], ["deletion", 976], ["of", 985], ["three", 988], ["nucleotides", 994], ["(", 1006], ["CTT", 1007], [")", 1010], ["identified", 1012], ["in", 1023], ["the", 1026], ["KCNQ1", 1030], ["gene", 1036], ["caused", 1041], ["the", 1048], ["loss", 1052], ["of", 1057], ["a", 1060], ["single", 1062], ["phenylalanine", 1069], ["residue", 1083], ["at", 1091], ["position", 1094], ["339", 1103], ["(", 1107], ["KCNQ1-deltaF339", 1108], [")", 1123], [".", 1124], ["Electrophysiological", 1126], ["measurements", 1147], ["in", 1160], ["the", 1163], ["presence", 1167], ["and", 1176], ["absence", 1180], ["of", 1188], ["the", 1191], ["regulatory", 1195], ["beta", 1206], ["-", 1210], ["subunit", 1211], ["KCNE1", 1219], ["revealed", 1225], ["that", 1234], ["mutant", 1239], ["and", 1246], ["wild", 1250], ["type", 1255], ["forms", 1260], ["of", 1266], ["an", 1269], ["N", 1272], ["-", 1273], ["terminal", 1274], ["truncated", 1283], ["KCNQ1", 1293], ["subunit", 1299], ["(", 1307], ["isoform", 1308], ["2", 1316], [")", 1317], ["caused", 1319], ["much", 1326], ["stronger", 1331], ["dominant", 1340], ["-", 1348], ["negative", 1349], ["current", 1358], ["reduction", 1366], ["than", 1376], ["the", 1381], ["mutant", 1385], ["form", 1392], ["of", 1397], ["the", 1400], ["full", 1404], ["-", 1408], ["length", 1409], ["KCNQ1", 1416], ["subunit", 1422], ["(", 1430], ["isoform", 1431], ["1", 1439], [")", 1440], [".", 1441], ["This", 1443], ["study", 1448], ["highlights", 1454], ["the", 1465], ["functional", 1469], ["relevance", 1480], ["of", 1490], ["the", 1493], ["truncated", 1497], ["KCNQ1", 1507], ["splice", 1513], ["variant", 1520], ["(", 1528], ["isoform", 1529], ["2", 1537], [")", 1538], ["in", 1540], ["establishment", 1543], ["and", 1557], ["mode", 1561], ["of", 1566], ["inheritance", 1569], ["in", 1581], ["long", 1584], ["QT", 1589], ["syndrome", 1592], [".", 1600], ["In", 1602], ["the", 1605], ["RWS", 1609], ["family", 1613], ["presented", 1620], ["here", 1630], [",", 1634], ["the", 1636], ["autosomal", 1640], ["-", 1649], ["dominant", 1650], ["trait", 1659], ["is", 1665], ["caused", 1668], ["by", 1675], ["multiple", 1678], ["dominant", 1687], ["-", 1695], ["negative", 1696], ["effects", 1705], ["provoked", 1713], ["by", 1722], ["heteromultimeric", 1725], ["channels", 1742], ["formed", 1751], ["by", 1758], ["wild", 1761], ["type", 1766], ["and", 1771], ["mutant", 1775], ["KCNQ1-isoforms", 1782], ["in", 1797], ["combination", 1800], ["with", 1812], ["KCNE1", 1817], [".", 1822]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "The organization of chromatin into higher-order structures influences chromosome function and epigenetic gene regulation. Higher-order chromatin has been proposed to be nucleated by the covalent modification of histone tails and the subsequent establishment of chromosomal subdomains by non-histone modifier factors. Here we show that human SUV39H1 and murine Suv39h1--mammalian homologues of Drosophila Su(var)3-9 and of Schizosaccharomyces pombe clr4--encode histone H3-specific methyltransferases that selectively methylate lysine 9 of the amino terminus of histone H3 in vitro. We mapped the catalytic motif to the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity. Methylation of lysine 9 interferes with phosphorylation of serine 10, but is also influenced by pre-existing modifications in the amino terminus of H3. In vivo, deregulated SUV39H1 or disrupted Suv39h activity modulate H3 serine 10 phosphorylation in native chromatin and induce aberrant mitotic divisions. Our data reveal a functional interdependence of site-specific H3 tail modifications and suggest a dynamic mechanism for the regulation of higher-order chromatin.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d2b96659e02a4db4a080036e2a0c4128", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[99, 100]], "char_spans": [[644, 653]]}]}], "context_tokens": [["The", 0], ["organization", 4], ["of", 17], ["chromatin", 20], ["into", 30], ["higher", 35], ["-", 41], ["order", 42], ["structures", 48], ["influences", 59], ["chromosome", 70], ["function", 81], ["and", 90], ["epigenetic", 94], ["gene", 105], ["regulation", 110], [".", 120], ["Higher", 122], ["-", 128], ["order", 129], ["chromatin", 135], ["has", 145], ["been", 149], ["proposed", 154], ["to", 163], ["be", 166], ["nucleated", 169], ["by", 179], ["the", 182], ["covalent", 186], ["modification", 195], ["of", 208], ["histone", 211], ["tails", 219], ["and", 225], ["the", 229], ["subsequent", 233], ["establishment", 244], ["of", 258], ["chromosomal", 261], ["subdomains", 273], ["by", 284], ["non", 287], ["-", 290], ["histone", 291], ["modifier", 299], ["factors", 308], [".", 315], ["Here", 317], ["we", 322], ["show", 325], ["that", 330], ["human", 335], ["SUV39H1", 341], ["and", 349], ["murine", 353], ["Suv39h1", 360], ["-", 367], ["-mammalian", 368], ["homologues", 379], ["of", 390], ["Drosophila", 393], ["Su(var)3", 404], ["-", 412], ["9", 413], ["and", 415], ["of", 419], ["Schizosaccharomyces", 422], ["pombe", 442], ["clr4", 448], ["-", 452], ["-encode", 453], ["histone", 461], ["H3-specific", 469], ["methyltransferases", 481], ["that", 500], ["selectively", 505], ["methylate", 517], ["lysine", 527], ["9", 534], ["of", 536], ["the", 539], ["amino", 543], ["terminus", 549], ["of", 558], ["histone", 561], ["H3", 569], ["in", 572], ["vitro", 575], [".", 580], ["We", 582], ["mapped", 585], ["the", 592], ["catalytic", 596], ["motif", 606], ["to", 612], ["the", 615], ["evolutionarily", 619], ["conserved", 634], ["SET", 644], ["domain", 648], [",", 654], ["which", 656], ["requires", 662], ["adjacent", 671], ["cysteine", 680], ["-", 688], ["rich", 689], ["regions", 694], ["to", 702], ["confer", 705], ["histone", 712], ["methyltransferase", 720], ["activity", 738], [".", 746], ["Methylation", 748], ["of", 760], ["lysine", 763], ["9", 770], ["interferes", 772], ["with", 783], ["phosphorylation", 788], ["of", 804], ["serine", 807], ["10", 814], [",", 816], ["but", 818], ["is", 822], ["also", 825], ["influenced", 830], ["by", 841], ["pre", 844], ["-", 847], ["existing", 848], ["modifications", 857], ["in", 871], ["the", 874], ["amino", 878], ["terminus", 884], ["of", 893], ["H3", 896], [".", 898], ["In", 900], ["vivo", 903], [",", 907], ["deregulated", 909], ["SUV39H1", 921], ["or", 929], ["disrupted", 932], ["Suv39h", 942], ["activity", 949], ["modulate", 958], ["H3", 967], ["serine", 970], ["10", 977], ["phosphorylation", 980], ["in", 996], ["native", 999], ["chromatin", 1006], ["and", 1016], ["induce", 1020], ["aberrant", 1027], ["mitotic", 1036], ["divisions", 1044], [".", 1053], ["Our", 1055], ["data", 1059], ["reveal", 1064], ["a", 1071], ["functional", 1073], ["interdependence", 1084], ["of", 1100], ["site", 1103], ["-", 1107], ["specific", 1108], ["H3", 1117], ["tail", 1120], ["modifications", 1125], ["and", 1139], ["suggest", 1143], ["a", 1151], ["dynamic", 1153], ["mechanism", 1161], ["for", 1171], ["the", 1175], ["regulation", 1179], ["of", 1190], ["higher", 1193], ["-", 1199], ["order", 1200], ["chromatin", 1206], [".", 1215]]}
{"context": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. Here, we report on a 14-month-old boy with a reverse phenotype of Sotos syndrome due to the reciprocal duplication of the 5q35.3 region, including the NSD1 gene, detected by array CGH. The phenotype includes delayed bone age, microcephaly, seizures, and failure to thrive. Our case suggests that the gene dosage effect of the NSD1 gene is the likely cause for the reversed phenotype of Sotos syndrome in this patient.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "4dacfcd587cf4e6f8eed4e508e7a454e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[109, 110], [75, 76], [3, 4]], "char_spans": [[630, 638], [455, 463], [26, 34]]}]}], "context_tokens": [["Haploinsufficiency", 0], ["of", 19], ["the", 22], ["NSD1", 26], ["gene", 31], ["due", 36], ["to", 40], ["5q35", 43], ["microdeletions", 48], ["or", 63], ["intragenic", 66], ["mutations", 77], ["is", 87], ["the", 90], ["major", 94], ["cause", 100], ["of", 106], ["Sotos", 109], ["syndrome", 115], ["characterized", 124], ["by", 138], ["generalized", 141], ["overgrowth", 153], [",", 163], ["large", 165], ["hands", 171], ["and", 177], ["feet", 181], ["with", 186], ["advanced", 191], ["bone", 200], ["age", 205], [",", 208], ["craniofacial", 210], ["dysmorphic", 223], ["features", 234], [",", 242], ["learning", 244], ["disability", 253], [",", 263], ["and", 265], ["possible", 269], ["susceptibility", 278], ["to", 293], ["tumors", 296], [".", 302], ["Here", 304], [",", 308], ["we", 310], ["report", 313], ["on", 320], ["a", 323], ["14-month", 325], ["-", 333], ["old", 334], ["boy", 338], ["with", 342], ["a", 347], ["reverse", 349], ["phenotype", 357], ["of", 367], ["Sotos", 370], ["syndrome", 376], ["due", 385], ["to", 389], ["the", 392], ["reciprocal", 396], ["duplication", 407], ["of", 419], ["the", 422], ["5q35.3", 426], ["region", 433], [",", 439], ["including", 441], ["the", 451], ["NSD1", 455], ["gene", 460], [",", 464], ["detected", 466], ["by", 475], ["array", 478], ["CGH", 484], [".", 487], ["The", 489], ["phenotype", 493], ["includes", 503], ["delayed", 512], ["bone", 520], ["age", 525], [",", 528], ["microcephaly", 530], [",", 542], ["seizures", 544], [",", 552], ["and", 554], ["failure", 558], ["to", 566], ["thrive", 569], [".", 575], ["Our", 577], ["case", 581], ["suggests", 586], ["that", 595], ["the", 600], ["gene", 604], ["dosage", 609], ["effect", 616], ["of", 623], ["the", 626], ["NSD1", 630], ["gene", 635], ["is", 640], ["the", 643], ["likely", 647], ["cause", 654], ["for", 660], ["the", 664], ["reversed", 668], ["phenotype", 677], ["of", 687], ["Sotos", 690], ["syndrome", 696], ["in", 705], ["this", 708], ["patient", 713], [".", 720]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "The amino acid selenocysteine is encoded by UGA, usually a stop codon, thus requiring a specialized machinery to enable its incorporation into selenoproteins. The machinery comprises the tRNA(Sec), a 3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS), which is mandatory for recoding UGA as a Sec codon, the SECIS Binding Protein 2 (SBP2), and other proteins. Little is known about the molecular mechanism and, in particular, when, where, and how the SECIS and SBP2 contact the ribosome. Previous work by others used the isolated SECIS RNA to address this question. Here, we developed a novel approach using instead engineered minimal selenoprotein mRNAs containing SECIS elements derivatized with photoreactive groups. By cross-linking experiments in rabbit reticulocyte lysate, new information could be gained about the SBP2 and SECIS contacts with components of the translation machinery at various translation steps. In particular, we found that SBP2 was bound only to the SECIS in 48S pre-initiation and 80S pretranslocation complexes. In the complex where the Sec-tRNA(Sec) was accommodated to the A site but transpeptidation was blocked, SBP2 bound the ribosome and possibly the SECIS element as well, and the SECIS had flexible contacts with the 60S ribosomal subunit involving several ribosomal proteins. Altogether, our findings led to broadening our understanding about the unique mechanism of selenocysteine incorporation in mammals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "00475180d274498e9dad745b5ff8c048", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[176, 176], [59, 59], [125, 125], [90, 90], [214, 214], [221, 221], [44, 44], [151, 151], [104, 104]], "char_spans": [[997, 1001], [328, 332], [686, 690], [471, 475], [1206, 1210], [1237, 1241], [264, 268], [851, 855], [550, 554]]}]}], "context_tokens": [["The", 0], ["amino", 4], ["acid", 10], ["selenocysteine", 15], ["is", 30], ["encoded", 33], ["by", 41], ["UGA", 44], [",", 47], ["usually", 49], ["a", 57], ["stop", 59], ["codon", 64], [",", 69], ["thus", 71], ["requiring", 76], ["a", 86], ["specialized", 88], ["machinery", 100], ["to", 110], ["enable", 113], ["its", 120], ["incorporation", 124], ["into", 138], ["selenoproteins", 143], [".", 157], ["The", 159], ["machinery", 163], ["comprises", 173], ["the", 183], ["tRNA(Sec", 187], [")", 195], [",", 196], ["a", 198], ["3'-UTR", 200], ["mRNA", 207], ["stem", 212], ["-", 216], ["loop", 217], ["termed", 222], ["SElenoCysteine", 229], ["Insertion", 244], ["Sequence", 254], ["(", 263], ["SECIS", 264], [")", 269], [",", 270], ["which", 272], ["is", 278], ["mandatory", 281], ["for", 291], ["recoding", 295], ["UGA", 304], ["as", 308], ["a", 311], ["Sec", 313], ["codon", 317], [",", 322], ["the", 324], ["SECIS", 328], ["Binding", 334], ["Protein", 342], ["2", 350], ["(", 352], ["SBP2", 353], [")", 357], [",", 358], ["and", 360], ["other", 364], ["proteins", 370], [".", 378], ["Little", 380], ["is", 387], ["known", 390], ["about", 396], ["the", 402], ["molecular", 406], ["mechanism", 416], ["and", 426], [",", 429], ["in", 431], ["particular", 434], [",", 444], ["when", 446], [",", 450], ["where", 452], [",", 457], ["and", 459], ["how", 463], ["the", 467], ["SECIS", 471], ["and", 477], ["SBP2", 481], ["contact", 486], ["the", 494], ["ribosome", 498], [".", 506], ["Previous", 508], ["work", 517], ["by", 522], ["others", 525], ["used", 532], ["the", 537], ["isolated", 541], ["SECIS", 550], ["RNA", 556], ["to", 560], ["address", 563], ["this", 571], ["question", 576], [".", 584], ["Here", 586], [",", 590], ["we", 592], ["developed", 595], ["a", 605], ["novel", 607], ["approach", 613], ["using", 622], ["instead", 628], ["engineered", 636], ["minimal", 647], ["selenoprotein", 655], ["mRNAs", 669], ["containing", 675], ["SECIS", 686], ["elements", 692], ["derivatized", 701], ["with", 713], ["photoreactive", 718], ["groups", 732], [".", 738], ["By", 740], ["cross", 743], ["-", 748], ["linking", 749], ["experiments", 757], ["in", 769], ["rabbit", 772], ["reticulocyte", 779], ["lysate", 792], [",", 798], ["new", 800], ["information", 804], ["could", 816], ["be", 822], ["gained", 825], ["about", 832], ["the", 838], ["SBP2", 842], ["and", 847], ["SECIS", 851], ["contacts", 857], ["with", 866], ["components", 871], ["of", 882], ["the", 885], ["translation", 889], ["machinery", 901], ["at", 911], ["various", 914], ["translation", 922], ["steps", 934], [".", 939], ["In", 941], ["particular", 944], [",", 954], ["we", 956], ["found", 959], ["that", 965], ["SBP2", 970], ["was", 975], ["bound", 979], ["only", 985], ["to", 990], ["the", 993], ["SECIS", 997], ["in", 1003], ["48S", 1006], ["pre", 1010], ["-", 1013], ["initiation", 1014], ["and", 1025], ["80S", 1029], ["pretranslocation", 1033], ["complexes", 1050], [".", 1059], ["In", 1061], ["the", 1064], ["complex", 1068], ["where", 1076], ["the", 1082], ["Sec", 1086], ["-", 1089], ["tRNA(Sec", 1090], [")", 1098], ["was", 1100], ["accommodated", 1104], ["to", 1117], ["the", 1120], ["A", 1124], ["site", 1126], ["but", 1131], ["transpeptidation", 1135], ["was", 1152], ["blocked", 1156], [",", 1163], ["SBP2", 1165], ["bound", 1170], ["the", 1176], ["ribosome", 1180], ["and", 1189], ["possibly", 1193], ["the", 1202], ["SECIS", 1206], ["element", 1212], ["as", 1220], ["well", 1223], [",", 1227], ["and", 1229], ["the", 1233], ["SECIS", 1237], ["had", 1243], ["flexible", 1247], ["contacts", 1256], ["with", 1265], ["the", 1270], ["60S", 1274], ["ribosomal", 1278], ["subunit", 1288], ["involving", 1296], ["several", 1306], ["ribosomal", 1314], ["proteins", 1324], [".", 1332], ["Altogether", 1334], [",", 1344], ["our", 1346], ["findings", 1350], ["led", 1359], ["to", 1363], ["broadening", 1366], ["our", 1377], ["understanding", 1381], ["about", 1395], ["the", 1401], ["unique", 1405], ["mechanism", 1412], ["of", 1422], ["selenocysteine", 1425], ["incorporation", 1440], ["in", 1454], ["mammals", 1457], [".", 1464]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f7e5563396b64495a72b3ad4feedde3e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[89, 90], [39, 40], [51, 52]], "char_spans": [[517, 526], [250, 259], [315, 324]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "Amyloid precursor protein (APP) is strongly related to the onset of Alzheimer's disease. It possesses cleavage sites for beta- and gamma-secretases, and the resulting cleaved products (amyloid-beta peptides) are capable of causing neurotoxicity. Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene. Here, we characterized APPSL transgenic mice (APPSL-Tg) to determine the effects of this mutation. We observed that both the amount of insoluble amyloid-beta and the ratio of amyloid-beta 42/40 increased promptly in the brain during 6-16 months of age. Amyloid-beta plaques were observed in whole brain sections at 12 months. In contrast, the spatial memory assessed by the Morris water maze task was already impaired at 3 months, which suggested that the APPSL-Tg mice may represent an early-onset model of familial Alzheimer's disease. Furthermore, the levels of LAMP-1, a marker protein of lysosome, increased in the brain at 28 months. Such LAMP-1 protein was detected around the amyloid-beta plaques at the hippocampal regions of the APPSL-Tg mice. Our results suggested that the increase in LAMP-1 was enhanced by the accumulation of amyloid-beta occurring during aging. Our findings coincided with the pathological hallmarks of Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "d8237f9d763b42d483bb971b70dd1706", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[13, 15], [244, 246], [168, 170]], "char_spans": [[68, 86], [1277, 1295], [859, 877]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["APP", 27], [")", 30], ["is", 32], ["strongly", 35], ["related", 44], ["to", 52], ["the", 55], ["onset", 59], ["of", 65], ["Alzheimer", 68], ["'s", 77], ["disease", 80], [".", 87], ["It", 89], ["possesses", 92], ["cleavage", 102], ["sites", 111], ["for", 117], ["beta-", 121], ["and", 127], ["gamma", 131], ["-", 136], ["secretases", 137], [",", 147], ["and", 149], ["the", 153], ["resulting", 157], ["cleaved", 167], ["products", 175], ["(", 184], ["amyloid", 185], ["-", 192], ["beta", 193], ["peptides", 198], [")", 206], ["are", 208], ["capable", 212], ["of", 220], ["causing", 223], ["neurotoxicity", 231], [".", 244], ["Such", 246], ["cleavage", 251], ["is", 260], ["promoted", 263], ["by", 272], ["the", 275], ["Swedish", 279], ["and", 287], ["London", 291], ["mutations", 298], ["(", 308], ["APPSwe", 309], ["/", 315], ["Lon", 316], [")", 319], ["inside", 321], ["the", 328], ["APP", 332], ["gene", 336], [".", 340], ["Here", 342], [",", 346], ["we", 348], ["characterized", 351], ["APPSL", 365], ["transgenic", 371], ["mice", 382], ["(", 387], ["APPSL", 388], ["-", 393], ["Tg", 394], [")", 396], ["to", 398], ["determine", 401], ["the", 411], ["effects", 415], ["of", 423], ["this", 426], ["mutation", 431], [".", 439], ["We", 441], ["observed", 444], ["that", 453], ["both", 458], ["the", 463], ["amount", 467], ["of", 474], ["insoluble", 477], ["amyloid", 487], ["-", 494], ["beta", 495], ["and", 500], ["the", 504], ["ratio", 508], ["of", 514], ["amyloid", 517], ["-", 524], ["beta", 525], ["42/40", 530], ["increased", 536], ["promptly", 546], ["in", 555], ["the", 558], ["brain", 562], ["during", 568], ["6", 575], ["-", 576], ["16", 577], ["months", 580], ["of", 587], ["age", 590], [".", 593], ["Amyloid", 595], ["-", 602], ["beta", 603], ["plaques", 608], ["were", 616], ["observed", 621], ["in", 630], ["whole", 633], ["brain", 639], ["sections", 645], ["at", 654], ["12", 657], ["months", 660], [".", 666], ["In", 668], ["contrast", 671], [",", 679], ["the", 681], ["spatial", 685], ["memory", 693], ["assessed", 700], ["by", 709], ["the", 712], ["Morris", 716], ["water", 723], ["maze", 729], ["task", 734], ["was", 739], ["already", 743], ["impaired", 751], ["at", 760], ["3", 763], ["months", 765], [",", 771], ["which", 773], ["suggested", 779], ["that", 789], ["the", 794], ["APPSL", 798], ["-", 803], ["Tg", 804], ["mice", 807], ["may", 812], ["represent", 816], ["an", 826], ["early", 829], ["-", 834], ["onset", 835], ["model", 841], ["of", 847], ["familial", 850], ["Alzheimer", 859], ["'s", 868], ["disease", 871], [".", 878], ["Furthermore", 880], [",", 891], ["the", 893], ["levels", 897], ["of", 904], ["LAMP-1", 907], [",", 913], ["a", 915], ["marker", 917], ["protein", 924], ["of", 932], ["lysosome", 935], [",", 943], ["increased", 945], ["in", 955], ["the", 958], ["brain", 962], ["at", 968], ["28", 971], ["months", 974], [".", 980], ["Such", 982], ["LAMP-1", 987], ["protein", 994], ["was", 1002], ["detected", 1006], ["around", 1015], ["the", 1022], ["amyloid", 1026], ["-", 1033], ["beta", 1034], ["plaques", 1039], ["at", 1047], ["the", 1050], ["hippocampal", 1054], ["regions", 1066], ["of", 1074], ["the", 1077], ["APPSL", 1081], ["-", 1086], ["Tg", 1087], ["mice", 1090], [".", 1094], ["Our", 1096], ["results", 1100], ["suggested", 1108], ["that", 1118], ["the", 1123], ["increase", 1127], ["in", 1136], ["LAMP-1", 1139], ["was", 1146], ["enhanced", 1150], ["by", 1159], ["the", 1162], ["accumulation", 1166], ["of", 1179], ["amyloid", 1182], ["-", 1189], ["beta", 1190], ["occurring", 1195], ["during", 1205], ["aging", 1212], [".", 1217], ["Our", 1219], ["findings", 1223], ["coincided", 1232], ["with", 1242], ["the", 1247], ["pathological", 1251], ["hallmarks", 1264], ["of", 1274], ["Alzheimer", 1277], ["'s", 1286], ["disease", 1289], [".", 1296]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The McLeod syndrome is an X-linked neuroacanthocytosis manifesting with myopathy and progressive chorea. It is caused by mutations of the XK gene encoding the XK protein, a putative membrane transport protein of yet unknown function. In erythroid tissues, XK forms a functional complex with the Kell glycoprotein. Here, we present an immunohistochemical study in skeletal muscle of normal controls and a McLeod patient with a XK gene point mutation (C977T) using affinity-purified antibodies against XK and Kell proteins. Histological examination of the affected muscle revealed the typical pattern of McLeod myopathy including type 2 fiber atrophy. In control muscles, Kell immunohistochemistry stained sarcoplasmic membranes. XK immunohistochemistry resulted in a type 2 fiber-specific intracellular staining that was most probably confined to the sarcoplasmic reticulum. In contrast, there was only a weak background signal without a specific staining pattern for XK and Kell in the McLeod muscle. Our results demonstrate that the lack of physiological XK expression correlates to the type 2 fiber atrophy in McLeod myopathy, and suggest that the XK protein represents a crucial factor for the maintenance of normal muscle structure and function.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "f252703de7194f1983547f4bf860ba40", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [27, 27], [44, 44], [87, 87], [23, 23], [73, 73], [121, 121], [175, 175], [159, 159]], "char_spans": [[1150, 1151], [159, 160], [256, 257], [500, 501], [138, 139], [426, 427], [728, 729], [1056, 1057], [967, 968]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["manifesting", 55], ["with", 67], ["myopathy", 72], ["and", 81], ["progressive", 85], ["chorea", 97], [".", 103], ["It", 105], ["is", 108], ["caused", 111], ["by", 118], ["mutations", 121], ["of", 131], ["the", 134], ["XK", 138], ["gene", 141], ["encoding", 146], ["the", 155], ["XK", 159], ["protein", 162], [",", 169], ["a", 171], ["putative", 173], ["membrane", 182], ["transport", 191], ["protein", 201], ["of", 209], ["yet", 212], ["unknown", 216], ["function", 224], [".", 232], ["In", 234], ["erythroid", 237], ["tissues", 247], [",", 254], ["XK", 256], ["forms", 259], ["a", 265], ["functional", 267], ["complex", 278], ["with", 286], ["the", 291], ["Kell", 295], ["glycoprotein", 300], [".", 312], ["Here", 314], [",", 318], ["we", 320], ["present", 323], ["an", 331], ["immunohistochemical", 334], ["study", 354], ["in", 360], ["skeletal", 363], ["muscle", 372], ["of", 379], ["normal", 382], ["controls", 389], ["and", 398], ["a", 402], ["McLeod", 404], ["patient", 411], ["with", 419], ["a", 424], ["XK", 426], ["gene", 429], ["point", 434], ["mutation", 440], ["(", 449], ["C977", 450], ["T", 454], [")", 455], ["using", 457], ["affinity", 463], ["-", 471], ["purified", 472], ["antibodies", 481], ["against", 492], ["XK", 500], ["and", 503], ["Kell", 507], ["proteins", 512], [".", 520], ["Histological", 522], ["examination", 535], ["of", 547], ["the", 550], ["affected", 554], ["muscle", 563], ["revealed", 570], ["the", 579], ["typical", 583], ["pattern", 591], ["of", 599], ["McLeod", 602], ["myopathy", 609], ["including", 618], ["type", 628], ["2", 633], ["fiber", 635], ["atrophy", 641], [".", 648], ["In", 650], ["control", 653], ["muscles", 661], [",", 668], ["Kell", 670], ["immunohistochemistry", 675], ["stained", 696], ["sarcoplasmic", 704], ["membranes", 717], [".", 726], ["XK", 728], ["immunohistochemistry", 731], ["resulted", 752], ["in", 761], ["a", 764], ["type", 766], ["2", 771], ["fiber", 773], ["-", 778], ["specific", 779], ["intracellular", 788], ["staining", 802], ["that", 811], ["was", 816], ["most", 820], ["probably", 825], ["confined", 834], ["to", 843], ["the", 846], ["sarcoplasmic", 850], ["reticulum", 863], [".", 872], ["In", 874], ["contrast", 877], [",", 885], ["there", 887], ["was", 893], ["only", 897], ["a", 902], ["weak", 904], ["background", 909], ["signal", 920], ["without", 927], ["a", 935], ["specific", 937], ["staining", 946], ["pattern", 955], ["for", 963], ["XK", 967], ["and", 970], ["Kell", 974], ["in", 979], ["the", 982], ["McLeod", 986], ["muscle", 993], [".", 999], ["Our", 1001], ["results", 1005], ["demonstrate", 1013], ["that", 1025], ["the", 1030], ["lack", 1034], ["of", 1039], ["physiological", 1042], ["XK", 1056], ["expression", 1059], ["correlates", 1070], ["to", 1081], ["the", 1084], ["type", 1088], ["2", 1093], ["fiber", 1095], ["atrophy", 1101], ["in", 1109], ["McLeod", 1112], ["myopathy", 1119], [",", 1127], ["and", 1129], ["suggest", 1133], ["that", 1141], ["the", 1146], ["XK", 1150], ["protein", 1153], ["represents", 1161], ["a", 1172], ["crucial", 1174], ["factor", 1182], ["for", 1189], ["the", 1193], ["maintenance", 1197], ["of", 1209], ["normal", 1212], ["muscle", 1219], ["structure", 1226], ["and", 1236], ["function", 1240], [".", 1248]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
